S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:ENLV

Enlivex Therapeutics - ENLV Stock Forecast, Price & News

$4.36
-0.01 (-0.23%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.30
▼
$4.43
50-Day Range
$3.74
▼
$4.68
52-Week Range
$3.62
▼
$8.64
Volume
50,214 shs
Average Volume
30,982 shs
Market Capitalization
$80.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Enlivex Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
244.0% Upside
$15.00 Price Target
Short Interest
Healthy
0.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.68) to ($1.55) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.45 out of 5 stars

Medical Sector

966th out of 1,030 stocks

Pharmaceutical Preparations Industry

467th out of 502 stocks

See Top Rated MarketRank™ Stocks Here
ENLV stock logo

About Enlivex Therapeutics (NASDAQ:ENLV) Stock

Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.

Receive ENLV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENLV Stock News Headlines

January 27, 2023 | americanbankingnews.com
Brokers Offer Predictions for Enlivex Therapeutics Ltd.'s FY2022 Earnings (NASDAQ:ENLV)
January 25, 2023 | msn.com
Enlivex cleared to expand clinical trial for cell therapy candidate
February 3, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 21, 2023 | reuters.com
ENLV.O - | Stock Price & Latest News | Reuters
January 4, 2023 | ca.finance.yahoo.com
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
January 4, 2023 | finance.yahoo.com
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium
December 6, 2022 | uk.finance.yahoo.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 5, 2022 | finance.yahoo.com
Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update
February 3, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
December 2, 2022 | finance.yahoo.com
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
November 29, 2022 | benzinga.com
FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies
November 28, 2022 | finance.yahoo.com
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 15, 2022 | benzinga.com
Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment
November 15, 2022 | benzinga.com
Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment
November 15, 2022 | finance.yahoo.com
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
November 11, 2022 | finance.yahoo.com
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
November 10, 2022 | finance.yahoo.com
Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
November 1, 2022 | benzinga.com
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
October 25, 2022 | proactiveinvestors.com
Enlivex Therapeutics says strong cash runway will support progress of its immunotherapy candidate
October 7, 2022 | nasdaq.com
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
October 3, 2022 | finance.yahoo.com
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
September 16, 2022 | morningstar.com
Enlivex Therapeutics Ltd ENLV Stock Chart
September 13, 2022 | finance.yahoo.com
Enlivex to Present at Upcoming Investor and Media Conferences
September 12, 2022 | finance.yahoo.com
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
September 6, 2022 | finance.yahoo.com
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
August 29, 2022 | finance.yahoo.com
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
August 24, 2022 | investing.com
Enlivex Therapeutics Ltd. Misses Q2 EPS by 9c
See More Headlines
Receive ENLV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENLV Company Calendar

Last Earnings
12/05/2022
Today
2/02/2023
Next Earnings (Estimated)
5/05/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENLV
CUSIP
N/A
CIK
1596812
Web
www.enlivex.com
Phone
(728) 662-3301
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+244.0%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,470,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-38.86%
Return on Assets
-34.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.08
Quick Ratio
13.08

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.64 per share
Price / Book
0.94

Miscellaneous

Outstanding Shares
18,410,000
Free Float
16,151,000
Market Cap
$80.27 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Oren Hershkovitz
    Chief Executive Officer
  • Shachar Shlosberger
    Chief Financial Officer
  • Dror Mevorach
    Chief Scientific & Medical Officer
  • Odelia Ben-Shitrit
    Head-Clinical Operations
  • Einat Galamidi
    Vice President-Medical

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













ENLV Stock - Frequently Asked Questions

What is Enlivex Therapeutics' stock price forecast for 2023?

0 Wall Street analysts have issued 1-year target prices for Enlivex Therapeutics' shares. Their ENLV share price forecasts range from $15.00 to $15.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 242.5% from the stock's current price.
View analysts price targets for ENLV or view top-rated stocks among Wall Street analysts.

How have ENLV shares performed in 2023?

Enlivex Therapeutics' stock was trading at $3.9375 on January 1st, 2023. Since then, ENLV shares have increased by 11.2% and is now trading at $4.38.
View the best growth stocks for 2023 here.

When is Enlivex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our ENLV earnings forecast.

How were Enlivex Therapeutics' earnings last quarter?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) posted its quarterly earnings data on Monday, December, 5th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.02.

What other stocks do shareholders of Enlivex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enlivex Therapeutics investors own include VBI Vaccines (VBIV), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Fulcrum Therapeutics (FULC), Soleno Therapeutics (SLNO), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Enlivex Therapeutics' stock symbol?

Enlivex Therapeutics trades on the NASDAQ under the ticker symbol "ENLV."

Who are Enlivex Therapeutics' major shareholders?

Enlivex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Enlivex Therapeutics?

Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enlivex Therapeutics' stock price today?

One share of ENLV stock can currently be purchased for approximately $4.38.

How much money does Enlivex Therapeutics make?

Enlivex Therapeutics (NASDAQ:ENLV) has a market capitalization of $80.64 million. The company earns $-14,470,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How can I contact Enlivex Therapeutics?

Enlivex Therapeutics' mailing address is 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR, TEL AVIV L3, 6522042. The official website for the company is www.enlivex.com. The company can be reached via phone at (728) 662-3301 or via email at info@enlivex.com.

This page (NASDAQ:ENLV) was last updated on 2/3/2023 by MarketBeat.com Staff